News from delmar pharmaceuticals A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( OTC-BB:DMPI)

Feb 04, 2016, 07:35 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Jan 13, 2016, 08:05 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals to Collaborate with MD Anderson Cancer Center on Development of DelMar's VAL-083 in Brain Cancer

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company") today announced that it has entered into a collaboration with the...

Jan 05, 2016, 07:00 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals to Present at the Biotech Showcase™ 2016 on January 12, 2016

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Nov 23, 2015, 08:05 ET
DelMar Pharmaceuticals

DelMar Pharmaceuticals Updates VAL-083 Clinical Trial in Refractory Glioblastoma Multiforme at Society for Neuro-Oncology Annual Meeting

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Nov 19, 2015, 08:05 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals to Present at the 8th Annual LD Micro Main Event on December 2, 2015

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Nov 17, 2015, 08:05 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Nov 13, 2015, 07:35 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals Presents Data Summarizing the Potential of VAL-083 as a New Treatment Option for Resistant Cancers

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Nov 11, 2015, 07:35 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development...

Nov 10, 2015, 08:05 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals Collaborators Present Data on the Unique Molecular Mechanisms Responsible for VAL-083 Activity Against Cancer

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Nov 09, 2015, 16:01 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals to Present Updated Phase II Safety and Efficacy Data on VAL-083 in Refractory Glioblastoma Multiforme

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Nov 06, 2015, 12:15 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals Presents Positive Data on the Benefit of VAL-083 in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC)

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Nov 05, 2015, 09:15 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals to Present at the SeeThruEquity Microcap Investor Forum on November 12, 2015

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Oct 21, 2015, 08:05 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals Announces the Completion of Enrollment in its Phase II Expansion Study of VAL-083 in Refractory Glioblastoma Multiforme

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Oct 19, 2015, 07:00 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals Presents Positive Preclinical Data on VAL-083 as a Promising Treatment for Ovarian Cancer

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Oct 14, 2015, 08:00 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals to Present at the 14th Annual BIO Investor Forum

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Oct 13, 2015, 08:00 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals Launches Digital Corporate Communication Channels

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Sep 29, 2015, 07:00 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals to Present Data on the Promising Potential of VAL-083 in the Treatment of Pediatric Brain Tumors

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Sep 28, 2015, 08:21 ET
OTC Markets Group, operator of financial markets for 10,000 U.S. and global securities.

DelMar Pharmaceuticals to Present an Interactive Live Webcast at VirtualInvestorConferences.com on October 1, 2015

- Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual event on Oct. 1 at 10:00 a.m....

Sep 10, 2015, 07:05 ET
DelMar Pharmaceuticals Logo

DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme at GBM2015

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...

Sep 08, 2015, 11:30 ET

DelMar Pharmaceuticals Presents Clinical Protocol for Advancement of VAL-083 into Phase IV Studies as a Treatment for Non-Small Cell Lung Cancer

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and...